ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2330

Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study

Siba Raychaudhuri1, Smriti K Raychaudhuri2, Jessica A. Walsh3, Gail Kerr4, Maureen Dubreuil5, Bernard Ng6, Elizabeth Chang7, Andreas Reimold8 and Liron Caplan9, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2Sacramento VA Medical Center, Davis, CA, 3Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5Boston University School of Medicine, Milton, MA, 6Veteran Affairs, Seattle, WA, 7PVAHCS, Phoenix, AZ, 8Dallas VA Medical Center, Dallas, TX, 9Rocky Mountain Regional VAMC, Aurora, CO

Meeting: ACR Convergence 2025

Keywords: Aging, Comorbidity, metabolic syndrome, Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Psoriasis and psoriatic arthritis (PsA) are associated with several comorbid conditions including metabolic disease, chronic kidney disease as well as mental health disorders. However, limited studies have been conducted on the impact of duration of PsA on comorbidities, and long-term change in practice to manage these comorbidities and improve patient care.The objective of this study is to determine the prevalence of comorbidities in patients with PsA in a cohort of elderly veterans and determine the correlation of prevalence of comorbidities with the duration of PsA.

Methods: Our cohort included PsA patients from PULSAR (Program to Understand Long-term Outcomes in Spondylarthritis) registry and VA Sacramento Medical Center. The duration of PsA disease was identified by age of onset of PsA noted in the databases and categorized as < 5 years, 6-10 years, 11-15 years, 16-20 years and >20 years. Various comorbidities were identified via ICD-10 codes (hypertension, hyperlipidemia, diabetes mellitus, gout and mental health disorders) and studied in these patients and classified according to the duration of PsA (Table 1).

Results: There were 220 patients available for study. PsA disease duration was as follows: < -5 years (73, 33.2%), 5-10 years (35,15.9%), 11-15 years (40,18.18%), 16-20 years (20, 9%) and more than 20 years (52, 23.6%). The prevalence of comorbidities in each of these groups was then calculated as listed in (Table 1). On subsequent comparison amongst the groups, as noted in Figure 1, the prevalence of hypertension increased with longer disease duration. A similar trend was not noted for the rest of the comorbidities. However, comorbidities that contribute to CVD risk were prevalent in one third to almost half of the PsA cohort, regardless of disease duration (Figure 1).

Conclusion: In this study, the prevalence of hypertension increased with PsA duration. Prevalence of the other comorbidities did not correlate with disease duration. Given the increased cardiovascular disease risks in PsA patients, our findings emphasize the need for hypertension control in PsA patients of longer disease duration. In addition, our findings demonstrate that PsA patients are at increased risk for several comorbidities, especially metabolic syndrome and mental health disorders irrespective of the duration of disease. So, preventive measures should be taken early in the disease course to screen and comprehensively manage these comorbidities and underlying psychosocial issues.

Supporting image 1Table 1: The prevalence of comorbidities in patients with psoriatic arthritis in elderly veterans: Data on the grouping of patients based on disease duration and prevalence of comorbidities.

Supporting image 2Figure 1: Bar diagram representative of correlation of prevalence of several comorbidities and

disease duration.


Disclosures: S. Raychaudhuri: AbbVie, 5, Amgen, 2, Eli Lilly, 2, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sun Pharma, 5; S. Raychaudhuri: None; J. Walsh: AbbVie, 2, 5, Amgen, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Merck, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Spyre, 2, 5, UCB, 2, 5; G. Kerr: Amgen, 2, Bristol-Myers Squibb(BMS), 2, CSL-Behring, 2, Janssen, 2, Novartis, 2, Pfizer, 2, Sanofi, 2, UCB, 2; M. Dubreuil: None; B. Ng: None; E. Chang: None; A. Reimold: None; L. Caplan: None.

To cite this abstract in AMA style:

Raychaudhuri S, Raychaudhuri S, Walsh J, Kerr G, Dubreuil M, Ng B, Chang E, Reimold A, Caplan L. Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans – A Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/correlation-of-comorbidities-with-psoriatic-arthritis-duration-in-elderly-veterans-a-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-of-comorbidities-with-psoriatic-arthritis-duration-in-elderly-veterans-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology